Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability of JADE101 in participants with IgA nephropathy. After: Measure: Incidence of treatment-emergent adverse events (safety and tolerability).
Recruitment status changed
Before: Not yet recruiting. After: Recruiting.